Alzheimer's disease (AD) is characterized by a progressive phenotypic downregulation of
markers within cholinergic basal forebrain (CBF) neurons, frank CBF cell loss and reduced …

Dementia conditions and memory deficits of different origins (vascular, metabolic and
primary neurodegenerative such as Alzheimer's and Parkinson's diseases) are getting more …

Whether mild cognitive impairment (MCI) has a distinct neuropathological profile that reflects
an intermediate state between no cognitive impairment and dementia is not clear. Identifying …

A growing body of evidence demonstrates the important role of the noradrenergic system in
the pathogenesis of many neurodegenerative processes, especially Alzheimer's disease …

Cognitive enhancers (nootropics) are drugs to treat cognition deficits in patients suffering
from Alzheimer's disease, schizophrenia, stroke, attention deficit hyperactivity disorder, or …

Alzheimer's disease (AD) is a profoundly life changing condition and once diagnosis occurs,
this is typically at a relatively late stage into the disease process. Therefore, a shift to earlier …

Neuropeptides represent by far the most common signalling molecules in the central
nervous system. They are involved in a wide range of physiological functions and can act as …

The intermediate nucleus (InM) in the preoptic area of the human brain, also known as the
sexually dimorphic nucleus of the preoptic area (SDN‐POA) and the interstitial nucleus of …

G-protein-coupled receptors (GPCRs) comprise the largest family of cell surface receptors
and are the major drug targets for the treatment of various human diseases. The lack of …

Like a number of neuropeptides, galanin can alter neural activity in brain areas that are
important for both stress-related behaviors and responses to drugs of abuse. Accordingly …